Researchers have been battling to find the cure for cancer since we began to understand what cancer really was. A cure is the ultimate goal, but most medical professionals and patients would be ecstatic even hearing about new treatments. Current cancer treatments often come rife with side effects so severe that many choose to forgo them altogether. Stopping the growth of malicious cancer cells is the main goal of treatment, and removing them altogether is even better. The problem is, this kind of treatment almost always causes damage to surrounding healthy cells.
A treatment that changes cancerous cells into healthy, supportive cells sounds ideal. Transforming malignant cells into antibodies that would attack remaining cancer cells sounds too good to be true. Thanks to a groundbreaking study by scientists at The Scripps Research Institute (TSRI), this new, powerful form of cancer therapy could really be on the horizon.
An Accidental Discovery
The laboratory team was working on therapies for certain immune cell or blood factor deficiencies when they noticed some unusual effects of antibodies on marrow cells. They had been searching for antibodies that activate growth-factor receptors on immature bone marrow cells, meaning the antibodies would be able to induce these cells to mature into specific blood cell types.
After successfully identifying a number of antibodies that activated the bone marrow cell-receptors this way, the researchers noticed that some of the antibodies were having unexpected effects on the cells. Some of them were maturing into cells that were radically different from what had been expected, such as neural cells. This got the team thinking, could this method be used to convert cancerous marrow cells (leukemia cells) into non-cancerous cells?
In the new study, Richard A. Lerner, institute professor and the Lita Annenberg Hazen professor of Immunochemistry at TSRI and senior investigator, teamed up with colleagues, including first author Kyungmoo Yea, an assistant professor of cellular and molecular biology at TSRI. They decided to test 20 of the recently discovered receptor-activating antibodies on acute myeloid leukemia cells taken from human patients. One of the antibodies ended up having an incredible impact on the leukemia cells.
Most acute myeloid leukemia cells have the thrombopoietin (TPO) receptor, a receptor the winning antibody selectively and potently activated in marrow cells. When the antibody was applied to healthy marrow cells, the cells matured into blood-platelet-producing cells (megakaryocytes). When applied to the acute myeloid leukemia cells, though, the antibody caused them to mature into dendritic cells, which are key support cells in the body’s immune system.
This alone would have been a success — the researchers had effectively transformed cancerous cells into non-cancerous, helpful immune system cells. The team pushed further, though, and found that with longer exposures to the antibodies and other regulated conditions, the dendritic cells matured even more. The final product was a group of cells that very closely resembled natural killer (NK) cells. One of the body’s rapid immune defenses, NK cells are capable of rapidly attacking potentially dangerous pathogens and tumors even if they don’t contain the biomarkers normally identified by other immune cells.
“That antibody could have turned those acute myeloid leukemia cells into a lot of other cell types, but somehow we were lucky enough to get NK cells,” Lerner said in a press release.
These induced NK cells possessed a few unique characteristics, observed by the team through electron microscopy. The cells possessed extending tendrils that had made their way through the outer membranes of closeby leukemia cells — the kind of cells they would still be, had they not been exposed to the antibody. In lab tests, the NK cells betrayed their former brethren at an impressive pace: a “modest” number of NK cells took out about 15 percent of the surrounding leukemic cell population in only 24 hours.
An interesting detail noted by the researchers is the purely fratricidal nature of the NK cells. They attacked only related leukemia cells, while unrelated breast cancer cells did not die off in large numbers when put into contact with the NK cells. The team is still unclear on why exactly the NK cells behave this way, but hypothesize that other, yet-to-be-discovered antibodies could be the key to turning other cancerous cell types into NK cells.
Lerner has named this type of therapy “fratricidins,” and pointed out that they would have several advantages. The antibodies would be clinically useful with little to no modification, and the high specificity of the NK cells would reduce the likelihood of damage to surrounding healthy cells. This would make fratricidins a possible treatment with much more tolerable effects than traditional treatments like chemotherapy.
On top of that, every cancer cell in a population is potentially convertible, so in a successful therapy the cancer-cell population might not just be reduced, but eliminated entirely.
The Latest on: Cancer Treatment Breakthrough
via Google News
The Latest on: Cancer Treatment Breakthrough
- Prostate Cancer Treatment – High Intensity Focused Ultrasoundon September 6, 2019 at 12:18 pm
prostate cancer is the most common cancer among men. Thanks to technology there's been a breakthrough in treating this disease. It's called High Intensity Focused Ultrasound. For more ...
- New Drug Screening Tool for Cancer Research Comes to Marketon September 6, 2019 at 11:49 am
“While our researchers have made some incredible discoveries in the lab, the real breakthrough will happen once cancer patients are more effectively treated using the precisely targeted therapeutic ...
- Neon Therapeutics Shares Are Flashing Brightly after Reporting Predictive Cancer Breakthroughon September 6, 2019 at 10:49 am
Neon Therapeutics lists that its clear mission is "to build a breakthrough oncology company creating ... dedicated to transforming the treatment of cancer by directing the immune system towards ...
- Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDAon September 6, 2019 at 9:40 am
Novartis AG NVS announced that the FDA has granted a Breakthrough ... the first-line treatment of patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC).
- FDA Grants Capmatinib Breakthrough Designation for MET+ NSCLCon September 6, 2019 at 8:22 am
The FDA has granted capmatinib (INC280) a breakthrough therapy designation as a first-line treatment for patients with MET exon 14 skipping mutation–positive non–small cell lung cancer (NSCLC). 1 The ...
- Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designationon September 6, 2019 at 4:52 am
Novartis’ investigational therapy capmatinib for patients with MET-mutated advanced non-small cell lung cancer (NSCLC) has received Breakthrough Therapy Designation ... which can in turn limit ...
- Novartis wins FDA's breakthrough tag for lung cancer hopefulon September 5, 2019 at 10:39 pm
ZURICH (Reuters) - Novartis has secured the U.S. Food and Drug Administration’s Breakthrough Therapy ... capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated ...
- Novartis joins Pfizer with FDA fast-track tag for lung cancer hopefulon September 5, 2019 at 10:37 pm
ZURICH (Reuters) - Novartis has nabbed the U.S. Food and Drug Administration's breakthrough therapy ... this year as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non ...
- FDA grants breakthrough designation to liver cancer liquid biopsy teston September 4, 2019 at 10:29 am
The Laboratory for Advanced Medicine announced via a press release that the FDA granted breakthrough ... cost associated with treatment.” Laboratory for Advanced Medicine previously reported data at ...
- Breast cancer gene could be key to developing targeted therapy for hepatoblastomaon September 3, 2019 at 11:17 pm
Hepatoblastoma is a rare form of liver cancer affecting just a few individuals per million ... aggressive forms of the disease leave some young patients with few treatment options and poor long-term ...
via Bing News